source
- AbbVie’s dual-acting myeloma drug etentamig meets main Phase 3 goal, showing longer progression-free survivalAbbVie announced that its bispecific antibody etentamig achieved the primary endpoint in a Phase 3 trial for patients with multiple myeloma who have progressed after two or more prior therapies. Th…
- Mid-size biotechs join White House Medicaid pricing program, gain tariff reliefNine mid-size drugmakers announced they will take part in the White House’s GENEROUS Medicaid pricing model, which ties U.S. Medicaid payments to the lowest prices paid abroad. In return, the comp…